chartexchange

IBRX270115C00013000
IBRX Jan 15 2027 13.00 Call
optionOPRA

EODOct 16, 2026
0.89USD-33.582%(-0.45)66Vol898OI
Loading…
Underlying
Underlying Price
$8.48
Type
Call
Strike
13
Expiration
Jan 15, 2027
DTE
87d
Moneyness
OTM
Intrinsic
$0.00
IBRX 13 Call Across Expirations
ExpirationDTELastChangeVolOpen Int
Oct 23, 20263d$0.10-73.68%2041
Oct 30, 202610d$0.15-21.05%433
Nov 6, 202617d$0.43+22.86%733
Nov 13, 202624d$0.43-18.87%88120
Nov 20, 202631d$0.25-39.02%21,184
Nov 27, 202638d——00
Dec 18, 202659d——00
Jan 15, 202787d$0.89-33.58%66898
Mar 19, 2027150d$2.00+42.86%523
Apr 16, 2027178d$2.11+24.12%4044
May 21, 2027213d$1.15+0.00%11
IBRX Nearby Strikes · Jan 15, 2027
StrikeLastChangeVolOpen IntMoneyness
5.5 C$4.50-12.62%17,668ITM
7.5 C$2.65-11.67%31521,039ITM
9 C$1.87-25.20%646,730OTM
10 C$1.55-26.19%2,28072,137OTM
11 C$1.15-32.35%39216,123OTM
12 C$1.00-31.03%71710,602OTM
13 C$0.89-33.58%66898OTM
14 C$1.00-16.67%103,110OTM
15 C$0.62-26.19%59813,429OTM
16 C$0.52-36.59%12,413OTM
17 C$0.45-32.84%42,431OTM
18 C$0.20-67.74%328OTM
20 C$0.29-25.64%3810,172OTM
IBRX Profile

immunitybio is a leading registration-stage immuno-oncology and infectious disease company activating both the innate (natural killer cell and macrophage) and adaptive (t cell) immune system. we are developing molecular and product platforms including n-803, aldoxorubicin, and a second-generation adenovirus vector, which are based upon our three key modalities of activating natural killer ('nk') and t cells, tumoricidal macrophages, and memory t cells.